Glenmede Trust’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$30.9M Sell
221,975
-27,375
-11% -$3.83M 0.15% 122
2025
Q4
$30.6M Buy
+249,350
New +$30.3M 0.15% 126
2025
Q1
$30.5M Buy
271,770
+8,394
+3% +$866K 0.16% 124
2024
Q4
$24.3M Sell
263,376
-28,672
-10% -$2.58M 0.12% 150
2024
Q3
$24.5M Sell
292,048
-34,711
-11% -$2.65M 0.12% 171
2024
Q2
$22.4M Sell
326,759
-33,427
-9% -$2.23M 0.11% 176
2024
Q1
$26.4M Sell
360,186
-13,090
-4% -$1.01M 0.13% 158
2023
Q4
$30.2M Buy
373,276
+8,296
+2% +$646K 0.16% 133
2023
Q3
$27.4M Buy
364,980
+39,619
+12% +$3.05M 0.16% 138
2023
Q2
$27M Sell
325,361
-243
-0.1% -$19.4K 0.15% 154
2023
Q1
$27M Buy
325,604
+55,315
+20% +$4.58M 0.15% 154
2022
Q4
$23.2M Buy
270,289
+103,696
+62% +$8.21M 0.14% 176
2022
Q3
$10.3M Buy
166,593
+1,098
+0.7% +$69.2K 0.06% 315
2022
Q2
$10.2M Sell
165,495
-40,886
-20% -$2.53M 0.06% 343
2022
Q1
$12.3M Buy
206,381
+10,215
+5% +$653K 0.06% 346
2021
Q4
$14.2M Sell
196,166
-11,219
-5% -$773K 0.07% 328
2021
Q3
$14.5M Sell
207,385
-15,551
-7% -$1.09M 0.08% 296
2021
Q2
$15.4M Sell
222,936
-45,066
-17% -$3.01M 0.08% 275
2021
Q1
$17.3M Sell
268,002
-268,308
-50% -$17.3M 0.09% 241
2020
Q4
$31.2M Sell
536,310
-146,992
-22% -$8.87M 0.17% 149
2020
Q3
$43.2M Sell
683,302
-156,876
-19% -$10.9M 0.26% 103
2020
Q2
$64.6M Buy
840,178
+83,410
+11% +$6.39M 0.4% 67
2020
Q1
$49.2M Hold
756,768
0.22% 123
2019
Q4
$49.2M Sell
756,768
-65,777
-8% -$4.28M 0.22% 123
2019
Q3
$52.1K Sell
822,545
-362,065
-31% -$23.7M 0.24% 117
2019
Q2
$80K Buy
1,184,610
+451,770
+62% +$29.7M 0.35% 68
2019
Q1
$47.6K Sell
732,840
-424,686
-37% -$28.2M 0.22% 135
2018
Q4
$72.4K Buy
1,157,526
+148,334
+15% +$10.4M 0.35% 67
2018
Q3
$77.9M Buy
1,009,192
+329,998
+49% +$24.9M 0.31% 72
2018
Q2
$48.1M Buy
679,194
+31,937
+5% +$2.26M 0.21% 145
2018
Q1
$46.4M Hold
647,257
0.19% 157
2017
Q4
$46.4M Buy
647,257
+23,751
+4% +$1.8M 0.19% 157
2017
Q3
$50.5M Buy
623,506
+187,362
+43% +$14.3M 0.22% 131
2017
Q2
$29.6M Hold
436,144
0.14% 225
2017
Q1
$29.6M Buy
436,144
+76,491
+21% +$5.38M 0.14% 225
2016
Q4
$25.8M Sell
359,653
-30,495
-8% -$2.27M 0.14% 247
2016
Q3
$30.9M Sell
390,148
-737,118
-65% -$59.9M 0.17% 199
2016
Q2
$94M Buy
1,127,266
+175,892
+18% +$15.6M 0.57% 24
2016
Q1
$87.4M Buy
951,374
+168,670
+22% +$15.2M 0.57% 31
2015
Q4
$79.2M Buy
782,704
+119,963
+18% +$12.5M 0.54% 31
2015
Q3
$65.1M Buy
662,741
+56,842
+9% +$6.31M 0.48% 39
2015
Q2
$70.9M Buy
605,899
+20,103
+3% +$2.2M 0.51% 35
2015
Q1
$57.5M Buy
585,796
+122,410
+26% +$12.4M 0.42% 45
2014
Q4
$43.7M Buy
463,386
+179,866
+63% +$18.6M 0.34% 62
2014
Q3
$30.2M Buy
283,520
+112,959
+66% +$11.1M 0.26% 89
2014
Q2
$14.1M Buy
170,561
+3,866
+2% +$301K 0.13% 239
2014
Q1
$11.8M Buy
166,695
+40,830
+32% +$3.2M 0.11% 263
2013
Q4
$9.45M Sell
125,865
-27,226
-18% -$1.9M 0.1% 278
2013
Q3
$9.62M Buy
153,091
+30,148
+25% +$1.8M 0.11% 234
2013
Q2
$6.3M Buy
+122,943
New +$6.41M 0.08% 282

Other funds holding GILD

Glenmede Trust's GILD Position: Q1 2026 in Review

Glenmede Trust reduced its Gilead Sciences (GILD) stake by 11% in Q1 2026, selling an estimated $3.83M and leaving 221,975 shares worth $30.9M. The position accounts for 0.15% of the portfolio, ranked #122.

Glenmede Trust first reported a position in GILD in Q2 2013 and has held it in 50 quarters since. The position peaked at $94M in Q2 2016. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Glenmede Trust held 221,975 shares of Gilead Sciences worth $30.9M as of Q1 2026.
  • Glenmede Trust sold 27,375 Gilead Sciences shares in Q1 2026, an estimated $3.83M.
  • Gilead Sciences made up 0.15% of Glenmede Trust's portfolio in Q1 2026, its #122 holding.
  • Glenmede Trust first reported a position in Gilead Sciences in Q2 2013 and has held it in 50 quarters since.
  • Glenmede Trust's Gilead Sciences position peaked at $94M in Q2 2016.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.